How are Östradiol and longevity related?

Estradiol (E2), the primary estrogen, influences several aging-related processes: it maintains bone density, supports cardiovascular health, and has neuroprotective effects. After menopause, E2 levels drop sharply, correlating with increased risks of osteoporosis, cardiovascular disease, and cognitive decline. Evidence from hormone replacement therapy (HRT) suggests that timely, individualized estrogen supplementation can improve healthspan and reduce mortality in certain subgroups. However, HRT also carries risks (e.g., breast cancer, thromboembolism), so benefit-risk assessment is crucial. The overall evidence is mixed: strong for specific outcomes (bone, cognition) but inconsistent for all-cause longevity. Direct-to-consumer hormone tests can measure E2, but single measurements are unreliable due to fluctuations and lack of clinical context. Self-supplementation is not advised. In summary, estradiol is a relevant but not standalone determinant of longevity; its role depends on timing, dosage, and individual health status.